PLC Announces Agreements to Distribute RenalGuard® in Central and South America, Turkey, and the United Kingdom

Signs Contracts with Girlow USA, Cenas and Pyramed at EuroPCR 2012

MILFORD, Mass. - PLC Systems Inc. (OTC: PLCSF), a company focused on innovative medical device technologies, today announced that it had signed new distribution agreements for RenalGuard® with Girlow USA, LLC, Cenas, Co., Ltd, and Pyramed Ltd., following its successful participation in EuroPCR in France earlier this month. Under terms of these agreements, PLC will expand its ability to distribute its innovative RenalGuard System(TM) to Mexico and several countries in Central America and South America, as well as Turkey and the United Kingdom, and initial stocking orders of RenalGuard consoles and single use sets have been purchased.

RenalGuard is CE-marked and can be sold immediately in the United Kingdom. Cenas has applied for Ministry of Health approval to market the product in Turkey. Girlow USA is registering RenalGuard for sale in Mexico and on a country by country basis in Central America and South America.

"These new distributors will enable PLC to expand the use of RenalGuard more deeply in important markets in Europe, and to continue our penetration of the growing healthcare markets in Mexico, Central America and South America," said Mark R. Tauscher, President and Chief Executive Officer of PLC Systems. "Our new partners are successful distributors in their respective markets and we believe their addition to our worldwide distributor network will help in our efforts to increase worldwide adoption of RenalGuard."

These agreements expand RenalGuard's distribution footprint into three new markets, complementing its existing presence in Europe, Israel, and Brazil and in select other countries around the world. PLC's U.S. pivotal trial of RenalGuard, which is required to secure approval from the U.S. Food & Drug Administration to market and sell RenalGuard in the U.S., began in late 2011.

About PLC Systems

PLC Systems Inc., headquartered in Milford, Mass., is a medical device company focused on innovative technologies for the cardiac and vascular markets. PLC's newest product, RenalGuard, has been developed to help prevent the onset of Contrast-Induced Nephropathy (CIN) in at-risk patients undergoing certain cardiac and vascular imaging procedures. The Product is CE-marked and is being marketed in Europe and selected countries around the world. Two investigator-sponsored European studies have demonstrated RenalGuard's effectiveness at preventing CIN. RenalGuard is being studied in a pivotal trial in the U.S., as required for approval by FDA.

PLC Systems, PLC Medical Systems, PLC, RenalGuard and RenalGuard System are trademarks of PLC Systems Inc.


Mary T. Conway



PLC Systems Inc.

More from Architectural & Civil Engineering Products

All Topics